Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Ready To Pull The Plug On Regeneron 'Life Support'

Executive Summary

Global R&D President Elias Zerhouni said Sanofi has the knowledge and skills it needs to discover antibody drugs internally and it's time to end the perception that Regeneron is keeping Sanofi's R&D humming.

You may also be interested in...



Sanofi R&D Chief Elias Zerhouni On Partnerships, Drug Targets, And Market Dynamics

As he steps down after a nine-year run as head of R&D, Zerhouni discusses the lessons he's learned and his major accomplishments.

Zerhouni Retires, Sanofi's New R&D Chief John Reed Brings Early Research Experience From Roche

Sanofi's longtime head of R&D Elias Zerhouni will step down in July. He was a steady hand at Sanofi amid tumultuous leadership transitions, but his tenure was marked by hits and misses.

Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology

The anti-PD-1 candidate is being developed in three cancer indications unserved by checkpoint inhibitors. Along with anti-CD38 isatuximab for multiple myeloma, this represents Sanofi's late push into IO.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel